US 12,479,904 B2
Methods of treating cytokine release syndrome by administering a molecule comprising a soluble tandem selectin glycoprotein ligand
Gray D Shaw, Plymouth, MA (US)
Appl. No. 16/957,169
Filed by Gray D Shaw, Plymouth, MA (US)
PCT Filed Dec. 20, 2018, PCT No. PCT/US2018/066979
§ 371(c)(1), (2) Date Jun. 23, 2020,
PCT Pub. No. WO2019/133454, PCT Pub. Date Jul. 4, 2019.
Claims priority of provisional application 62/611,957, filed on Dec. 29, 2017.
Prior Publication US 2024/0173378 A1, May 30, 2024
Int. Cl. C07K 14/705 (2006.01); A61K 38/17 (2006.01); A61K 40/10 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC C07K 14/70596 (2013.01) [A61K 38/177 (2013.01); A61K 40/10 (2025.01); A61K 40/31 (2025.01); A61K 40/4254 (2025.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 2319/30 (2013.01)] 16 Claims
 
1. A method of treating cytokine release syndrome (CRS), comprising administering an effective amount of a molecule to a subject in need thereof, wherein the molecule comprises a soluble tandem selectin glycoprotein ligand (TSGL) peptide comprising two or more PSGL-1 domains, and wherein each of the two or more PSGL-1 domains comprises amino acids 5 to 16 of SEQ ID NO: 2, wherein the molecule is administered in an amount effective to reduce the elevation of von Willebrand Factor or Angiopoietin-2 serum concentration.